SABR for oligometastatic renal cell carcinoma
- Journal Title
- Clinical and Translational Radiation Oncology
- Publication Type
- Review
- Abstract
- Stereotactic ablative body radiotherapy (SABR) aims to accurately deliver a higher than conventional dose of radiotherapy to a well-defined target tumour incorporating advanced immobilisation and imaging techniques. SABR is an emerging treatment option for primary kidney cancer especially when surgery is contraindicated. Increasingly, SABR is being incorporated into the management of low-volume stage IV kidney cancers to delay the need for systemic therapy or to prolong the duration of ongoing systemic treatment. This review will evaluate the evidence and limitations of SABR for oligometastatic renal cell carcinoma.
- Publisher
- Elsevier
- Keywords
- Oligometastasis; Renal cell carcinoma; Stereotactic ablative body radiotherapy; Stereotactic ablative radiotherapy
- Department(s)
- Radiation Oncology; Medical Oncology; Surgical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.ctro.2024.100739
- Open Access at Publisher's Site
https://doi.org/10.1016/j.ctro.2024.100739- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-04-02 01:27:18
Last Modified: 2024-04-02 01:33:27